World Congress on
Cancer Science and Therapy

Loai Aljerf is a Prof in the Department of Basic Sciences, Faculty of Dental Medicine/Damascus University. He is a specialist in analytical and industrial chemistry. He obtained many awards and published more than 50 peer-reviewed papers (two of them in French) in Environmental Sciences, Green Chemistry, Analytical Chemistry, Synthesis Chemistry, Concrete, Ceramics, Paper Industry, Petrochemical, Extraction, Separation, Lithium-Ion-Batteries, and Oral Chemistry. He is a partner in Advances in Cleaner Production Network, and a member of the German Chemical Society e.V. (GDCh), Asian Chemical Society, and the American University of Beirut. He is a member of the higher committee of the 6th International Workshop-Advance in Cleaner Production (São Paulo, Brazil (May 24th to 26th - 2017)) and in more than 20 conference organizing committees. Loai Aljerf is in the Cambridge Scholars Publishing-Life Science Advisory Board and an editor of more than 50 journals and a reviewer for Top journals in Industry, Chemical Engineering, and Environmental Chemistry.

Industrial Chemistry, Analytical Chemistry, Environmental Chemical Engineering, Environmental Science, Environmental Chemistry, Green Chemistry, Cement Industry, Ceramics, Paper Industry, Advances in Cleaner Production, Climate Change, Pollution, Wastewater Treatment, Air Pollution, Eco-friendly Biopolymers, Persistent Organic Pollutants, Polychlorinated biphenyls, Polycyclic Aromatic Hydrocarbons, Nanotechnology, Adsorption, Ecology and Natural Resources, Biodiversity, Sustainable Development, Waste Management, Environmental Management, Life Cycle Assessment, Ecodesign, Design for the Environment, Energy Labeling, Eco-efficiency, Chromatography, HPLC, GC, MS, AAS, Spectroscopy, and Lithium-Ion-Batteries.

Biography of Dr. Mojtaba Mafi: I am Dr. Mojtaba Mafi M.D., Medical Doctor/ Physician, graduated from Tehran university, School of Medicine with honor. I studied in neurosurgery ward and graduated with A score with thesis on Meningioma Brain Tumor during 6 years. With continuing my practice with special consideration on psychosomatic disorders, I completed many post graduate courses on health psychology, addiction medicine, sexual disorders therapy successfully. I passed many post graduate courses in Neuro, approved by Medical sciences university. As well, I have been passed post graduate courses on Nutrition, Gastroenterology and hepatology, Obesity treatment and diabetes approved by Tehran University of Medical sciences. I successfully passed more than 10 programs with certificates and membership in Iranian Association of Gastroenterology and Hepatology. Having honor of working as associate of Iran Hepatitis Network and Gastroenterology and Hepatology research center, Middle East Liver Diseases Center (MELD). This strong study background enabled me to successfully earn certificates on 3 programs: Updates of skin and treatment from Tehran university 2015 and course on skin care updates from Iranian society of practitioners on 2016, and during 2 years, I had passed Beauty and Skin care courses in South Korea and certified from Sunghuwan co Ltd for using and working of beauty technology, RF and IPL. I am director of fatty liver and related metabolic disorders study among Iranian families since 2015 and currently publishing the results of our study and research about fatty liver and hyperlipidemia, diabetes and nutrition as study director and clinician associate member of Iran Hepatitis Network. I am reviewer and associate editor of Hepatitis Monthly Journal and reviewer of journal of Clinical and Translational Hepatology. I am editorial board member of International Journal of Psychology and Neurosciences. I am certified graduate, verified reviewer and certified mentor of Publons academy in the field of Clinical Medicine and Hepatology. I am working clinically on patients with Brain Tumor and publishing my results on these topics: 1. Recurrent Meningioma 2. Trigeminal neuralgia 3. Radiation induced meningioma 4. Behavioral change in Brain Tumors 5. DVT prevalence and management among patients with meningioma And some others. I published reviews for articles on Brain Tumor Immunotherapy, CNS Tumor Guideline and Alzheimer disease in Elsevier and Kudos. My review on Alzheimer's disease article with specific DOI, was published in American Physiological Society. I have been invited by editor in chief of American Journal of Translational Medicine, to participate at International Conference of Translational Medicine, in Hawaii. My article entitled "Trigeminal Neuralgia caused by Brain Meningioma" has been accepted for oral presentation in world neurology and Neurodisorders Conference, Tokyo as keynote speaker. My article in the field of neuroscience about 'Recurrent Meningioma', etiologies and clinical aspects and tumor cellular pathology has been accepted for oral, poster presentation in World CNS Conference, France 2018. I am speaker of World Congress on Epilepsy in London. I am speaker of International conference on Central Nervous System and Therapeutics for my accepted article about recurrent Brain meningioma, in Paris 2018. I am speaker of Annual Congress on Neurology and Neuroscience (EuroNeurology 2019) for my accepted article on Brain stroke and meningioma held in paris,2019. My article on trigeminal neuralgia secondary to Brain tumor was accepted for oral presentation in World Brain Congress in Dubai,2018 as Honorable speaker. My article on pulmonary physiotherapy and rehabilitation related to Brain tumor surgery was accepted for oral presentation in 6th World Congress on Physiotherapy and Rehabilitation held in Dubai,2018. One of my works on diabetes and fatty liver as a scientific article has been accepted in 4th International Conference on Diabetes and Its Treatments at Dubai 2018 for oral presentation and publication and another one is about fatty liver and metabolism has been accepted for oral and poster presentation in International Conference of Gastroenterology and Hepatology, Thailand 2018 as Honorable speaker. I am speaker of International Conference on Obesity and Chronic diseases, 2018 in Dubai. My article on fatty liver and vascular disorders was accepted for oral presentation in 6th World Congress on Hypertension and Public Health in France, 2018. I am as well, Organizing Committee Member in International Conference of Obesity and Diet Imbalance in Indonesia, 2018 with accepted article on nutrition and fatty liver for oral presentation. My article on vascular disorders and ischemic heart disease was accepted for oral presentation in Global Congress on Cardiology and Interventional Cardiology held in Dubai, 2019. I am speaker of 7th International Conference on Hypertension and Healthcare in Finland, 2019, for my accepted article on vascular disorders related to fatty liver. I am invited Organizing Committee Member in 3rd International Conference on Alzheimer's Disease and Dementia held in London,2019. As distinguished speaker, my article has been accepted for oral presentation in 22th International Conference on New Horizons in Cardiology and Cardiologist Education held in Berlin, Germany 2019. I am speaker of 12th International Conference on Osteoporosis, Arthritis and Musculoskeletal disorders in London 2019, for my accepted article about discopathy secondary to brucellosis. I am speaker and Organizing Committee Member of 6th International Conference on Rare Disease and Orphan Drug 2019 in Dubai, for my accepted article about rare type of peptic ulcer. My article on psoriasis related to fatty liver was accepted for oral presentation in International Dermatology Conference: Skin and Body, held in Indonesia, 2018 as distinguished speaker. I am Organizing Committee Member of Annual Conference on Neurology and Neuroscience (EuroNeurology 2019) held in France. I am Organizing Committee Member (OCM) of pulsus group conferences in the field of Heart and Cardiology: - OCM of 5th International conference on vascular Biology and Surgeons Meeting London, 2019. - OCM of 2nd Global Heart congress, Osaka, Japan, 2019. - OCM of Global Congress on cardiology and International cardiology, Dubai, 2019. As well, I received organizing committee membership of 15th International conference on Metabolomics and systems Biology Japan. I am organizing committee member of World Congress on cancer science and therapy Rome, Italy. I am organizing committee member of world highest rank conferences in the field of neuroscience: - OCM of Global Experts Meeting on Advances in neurology and neuropsychiatry, Melbourne, 2019. - OCM of European Neurology congress Venice, Italy, 2019. - OCM of International conference on Addictive Disorders and Alcoholism, Brisbane, 2019. - OCM of 5th Global Experts Meeting on Parkinsons, Huntington's and Movement disorders, Japan. With honor I received Organizing Committee membership of 4th World congress on pediatric Neurology and pediatric surgery, Auckland. In the field of Neuroscience, I am Organizing committee member of 4th Annual conference on Brain Disorders, Neurology and Therapeutics, Spain. In scientific federation on Neuroscience, I achieved organizing committee membership of multiple conferences: - OCM of 30th Edition of International conference on Neurology and Neuroscience, Singapore and OCM of Alzheimer's and parkinsons conference, France, 2019. I am distinguished speaker and organizing committee member of 12th International conference on Osteoporosis, Arthritis and Musculoskeletal Disorders, London. As well, I am organizing committee member of International conference on Central nervous System and Neurological Surgeons, London, 2019.

Recurrent Meningioma, Trigeminal neuralgia, Radiation induced meningioma, Behavioral change in Brain Tumors, DVT prevalence and management among patients with meningioma And some others.

Dr. Alain L Fymat is a medical-physical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 425 publications including patents, books & monographs, book chapters, refereed articles). As invited/keynote speaker and member of organizing committees of international congresses and symposia, he has lectured extensively in the USA, Canada, Europe, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California). He is Editor-in-Chief, Honorable Editor or Editor of 32 medical-scientific Journals.

nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery across the brain protective barriers, and neurodegenerative disorders.

Dr. Sanjay Gupta is a Professor & Research Director and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and The Urology Institute at the University Hospitals Case Medical Center. He also holds secondary appointments in the Departments of Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta has joint appointment as Research Scientist at the Louis Stokes VA Medical Center, Cleveland, Ohio. Dr.Gupta obtained faculty position in 2002 at Case Western Reserve University, School of Medicine. Dr. Gupta’s research involves basic, translational and clinical areas of focus. In basic research his focus is to understand the risk factors and mechanisms of prostatic and bladder diseases and develop appropriate biomarkers for early detection and prognosis. Translational research focus is to identify novel targets to monitor the efficacy of various synthetic and natural agents and develop them as chemo preventatives/therapeutics. His clinical research interests are translation of bench research to its application in clinics. Dr. Gupta has authored some 150 publications, including book chapters, research articles and reviews,and has spoken at several occasions in cancer prevention symposium, seminars and meetings. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense(DOD), and other councils around the globe. He also serves on the Editorial board as well as reviewer for several prestigious scientific journals. His innovative research on basic and translational aspects has been featured on NBC‐5 news and highlighted in the Plain Dealer, and American Association for Cancer Research, and American Urological Association press release.

• Molecular mechanism(s) of prostate and bladder carcinogenesis • Role of inflammation in promoting prostate and bladder cancer • Biomarker(s) for detection and prognosis of prostate cancer • Identification and characterization of prostate cancer stem cells • Epigenetic mechanisms of gene silencing in prostate/bladder cancer and its reversal by natural agents • Molecular targets for prevention and treatment of prostate cancer • Chemoprevention of prostate/bladder cancer by naturally occurring and/or synthetic compounds • Drug repurposing, mechanism(s) of action with non-chemotherapeutic agents • Clinical trials with promising agents and their combinations

Professional experience in oncology circles, supported by multiple collaborations with major hospitals, allowed LOUIS CAZE to benefit from a reference fame as an Expert Support Care. First, Specialist lymphatic, muscular and circulatory LOUIS CAZE makes the total body approach his chosen field. It captures the benefits of physical-mental balance in the treatment of chronic diseases, and specializes in supportive care dedicated to cancer diseases. His collaboration with renowned organizations such as the Institute Gustave Roussy, was punctuated with exceptional professional and human experience. LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology.

LOUIS CAZE is involved in implementing a comprehensive approach to cancer patient, in a real project of care that optimizes patient's quality of life, ensuring the different key aspects of health: the well physical and psychological, but also the entire social and family interactions. After these experiences, LOUIS CAZE work for the development of Support Care, including the management of pain and psychology

I am a Medical Oncologist at Centro Clinico Oncologico, Division of Cancer Treatment, in Campinas, Sao Paulo, Brazil. I have M.Sc. and Ph.D. in Medical Sciences/Breast Medical Oncology from the State University of Campinas, UNICAMP, ranked as number one university from Latin America, according to Times Higher Education (2017). After obtaining my Board Certification in Medical Oncology in Brazil, I undertook a research scholar program at University of Texas MD Anderson Cancer Center for almost a year (2005). From 2006 to 2007, I was the Director of the Fellowship Program, and the PI of the Dept. of Clinical Trials at Hospital de Cancer de Barretos, one of the largest Cancer Centers in Brazil. From 2009 to 2013, I hold concomitant positions as Assistant Professor of Medicine at the Department of Medical Oncology at UNIARA, and as Researcher in the Department of Breast and Gynecology Oncology at UNICAMP, from 2008 to 2016. Since 2011, I am an Associate Attending Physician at the Centro Clinico Oncologico. I have 13 publications in journals such as Human Pathology, Journal of Clinical Oncology, and Annals of Oncology. In addition to delivering lectures around the country, I was the Principal or Co-Principal Investigator in more than 10 clinical trials covering breast, ovarian, and genitourinary cancers. I am a member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and Brazilian Society of Clinical Oncology (SBOC). My research interests include Immuno-Oncology, Breast and GYN tumors, Biomarkers, and GU cancers. Currently, I am an Editorial Board Member of six Cancer Journals

- Immuno-oncology - Breast and GYN tumors - Biomarkers - GU cancers

Dr. M. M. Karindas is the President of the WAMS, the World Academy of Medical Sciences, where he has been serving as its leader for more than two decades now. Having extensive experience as a research scientist in Clinical and Molecular Oncology, he is the holder of landmark research studies including the "Multicellular Origin of Cancer" and "Oncogenetic Evolution" as well as the OCA/OTA/OCATA and ECE research studies. He is the creator and writer of the KGS, the “Karindas Grading System”, the all-encompassing universal paradigm of tumor grading and a new integral method of clinical management in oncology. He is also the writer and declarant of the phenomenal "International Declaration of Oncogenesis" whose Part V (OCA/OTA/OCATA in Oncogenesis) will be presented by him at our World Congress of "Cancer Science and Therapy”-2018 in Madrid. Having his main research interests in "Oncogenesis", "Cancer Metastasis", "Cancer Stem Cells", "Tumor Cell Biology", "Molecular Oncopathology", "Cell Signaling", "Signal Transduction", "Extracellular Matrix" and the "Origin and Evolution of Cancer ", he is currently busy working on the creation and establishment of a new medical algorithmic system which will universally be used in oncology as well as other fields of medicine.

Oncogenesis, Cancer Metastasis, Cancer Stem Cells, Tumor Cell Biology, Molecular Oncopathology, Cell Signaling, Signal Transduction, Extracellular Matrix and the Origin and Evolution of Cancer

Inés Llamas Ramos has completed his PhD from University of Salamanca, Salamanca, Spain. She develops her professional work in Salamanca. She has been professor of the University of Salamanca, in the Department of Nursing and Physiotherapy. She has published articles about cancer and dry needling in reputed journals.

Cancer Immunology, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Joel I Osorio is an innovative businessman with a distinct entrepreneurial mindset concentrated adding value on areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. Dr. Osorio is the Founder, President, and CEO of RegenerAge Clinic and RegenerAge Beauty initiatives for transnational implementations. Vice President and International Clinical Developer for Bioquark, Inc., Chief Clinical Officer and Co-Founder at Reanima Advance Biosciences Project. Founder and CEO at Dr. Jois® and BiorganicAging® initiatives. He is the Medical Advisor at The Cracking Monkey® and HairLogica®. Chief Medical Officer at What Skin Needs™/WSN International Pty. Ltd. Within the academic and educational fields, Dr. Osorio acts as the Executive Vice President: Chairman of the WAMS Americas Division, member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He also functions as the Chief Executive Officer and a Founder at The Reprogramming Medicine Association. Dr. Osorio has appeared on several occasions on International T.V. shows, newspapers, radio shows, online discussion panels and has published multiple articles and medical reviews.

Regenerative Medicine

Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division and De la Parra Mobile Solutions and is former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil. Moreover, he is a member of the Board of Advisors, former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty, a member of the Board of Advisors, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also serves as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and is a member of the Board of Advisors and former Digital Media Director at Bioquark, Inc. He is also the former Latin America Region Manager and Digital Strategy adviser at CardiacSense and former CITO & Senior Partner at Cerezo Editores. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.

Neuroscience, Regenerative Medicine, Continued Medical Education, Information & Communications Technology, Biotechnology, Social Development

Dr. Brij. M. Gandhi, M.Sc., Ph.D. is presently CEO and founder of Neo BioMed Services (www.neobiomed.com), providing services and consultancy in health areas and regulatory issues related to biopharmaceuticals, pharmaceuticals, including stem cell and regenerative medicine. Dr. Gandhi had his Masters in Biochemistry from PAU and Ph.D. in Experimental Medicine from the University of Bergan, Norway. He was trained at the Massachusetts Institute of Technology, USA; London School of Hygiene and Tropical Medicine, London; National Institutes of Health, Maryland, USA; Hvidovre Hospital, Copenhagen and University of Bergan, Norway. Dr. Gandhi retired in 2006 as Adviser to the Government of India, Ministry of Science and Technology, Department of Biotechnology, managing promotion and policy related issues in biotechnology related to international collaborations, medical biotechnology, infrastructure development, animals and aquaculture biotechnology. Prior to that he was Research Scientist at AIIMS working on immunology of parasitic, bacterial and viral infections including amoebic diseases; hepatitis; liver diseases, IVD, food and nutritional health issues. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries with an experience of about 50 years of active service, as research scientist, science manager, adviser/consultant and over 155 publications.

Designs related to biotechnology, regulatory affairs biopharmaceuticals pharmaceuticals, biodefence, healthcare, lifesciences areas including stem cell and regenerative medicine.

Dr.Itzhak Avital, MD, MBA, FACS, is an established surgical oncologist and Chairman of the Department of Surgery at Saint Peter’s University Hospital in New Brunswick, New Jersey. Dr. Avital has 15 years of uniquely diversified experience in his specialty and a vast expertise in hepatobiliary surgery and hyper-thermic intraperitoneal chemotherapy treatment. Furthermore, Dr. Avital is the Executive Medical Director of The Bon Secours Cancer Institute in Virginia. Dr. Avital performed the first hyper-thermic intraoperative peritoneal chemotherapy (HIPEC) in central Virginia. In addition to his work with Saint Peter’s University Hospital, Dr. Avital is the CEO and Executive Medical Director of P8Medicine in Virginia and Professor of Surgery at Rutgers University/Robert Wood Johnson School of Medicine. He previously served as Head of the Gastroenterology and Hepatobiliary Malignancies Section, Surgery Branch, at the National Cancer Institute between 2006 and 2012. His international background includes his roles as Professor of Surgery at the Medical School of the University of Novi Sad in Serbia, Professor of Surgery at the Chinese National Colorectal Cancer Institute in Nanjing, China, and Visiting Professor of Surgery in the Department of Surgery at Hadassah Hospital in Israel. He is a fellow of the American College of Surgeons and member of the American Medical Association, the American Society of Clinical Oncology, the American Transplant Association, the Society of Surgical Oncology, the American College of Surgeons, the American Hepato-Pancreato-biliary Association, the International Society for Stem Cells Research, and the American Society for Peritoneal Surface Malignancies As a result of his outstanding performance in the field of surgical oncology, The International Association of HealthCare Professionals has selected Dr. Itzhak to be featured in the premier publication of The Leading Physicians of the World

Surgical oncologist

Achour Radhouane is associate professor at faculty of medicine of Tunis-Tunisia; He has published many basic and clinical articles in relation to gynecology and obstetrics. , his research interests include Rare Diseases in gynecology and prenatal diagnosis. He serves as associate professor, Emergency Department of Gynecology and Obstetrics in maternity and neonatology center Tunis Tunisia. He also serves as member of the editorial team for: Asian Pacific Journal of Reproduction, the Global Journal of Rare Diseases, Journal of Neonatal Biology, Current pediatric research, Obstetrics and Gynecology: Open access, Pediatrics and Health Research and Member of the Science Advisory Board.

Obstetrics and Gynecology

Dr Omnia Hassan Gohar, specialist of surgical oncology at DCI, Egypt. I have more than 12 years experience in surgical oncology. Dr. omnia have graduated with honors from Cairo University Faculty of Medicine in 2004. she has done master's degree in surgery in 2010, Ain Shams University. I have wide experience in variety of surgical oncological procedures and oncoplastic surgery especially breast and head - neck surgery. Dr. omnia have participated in researches about national statistics of cancer etiology and incidence.

oncoplastic surgery( breast cancer).

Youhe Gao received his M.D. from Peking Union Medical College, his Ph.D. from University of Connecticut and postdoctoral training from Beth Israel Deaconess Medical Center Harvard Medical School. He is the professor of Department of Physiology and Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College. His research interests include urine proteomics, biomarker discovery, protein interaction and related bioinformatics.

Biomarker discovery, proteomics

Thanos Mitrelias is a director with 14 years of entrepreneurial and scientific activity. He has been the Founding CEO of two spin offs the University of Cambridge: Cavendish Nano Therapeutics aimed at offering advanced medical systems for the targeted eradication of cancer tumour and Cambridge Bio Magnetics established to commercialize a platform and disruptive technology to address needs in clinical diagnostics and the oil and gas industries. He is a frequent speaker and panelist in international business and scientific fore, such as the Horasis Global Business Conferences, where he usually speaks on knowledge based economy and entrepreneurship. He has been at the University of Cambridge since 1994, has several patent applications, has raised more than $5.5 million for numerous projects and has wide scientific and commercial expertise in biotechnology and Nano science. Mitrelias has also set up Academy Capital Partners, a management company that aims to raise a substantial venture capital fund aimed mainly at investments in early stage technology companies with proven market traction and innovative products. He is also actively engaged in activities in the Middle East aimed at transforming the region’s economy to a knowledge based economy. Dr Mitrelias is also currently involved in setting up various multi-million collaborative international projects with academic institutions in Peru and Brazil. He holds a PhD in Natural Sciences from the University of Cambridge, an MSc (Eng) in Materials Science awarded with Distinction from the University of Liverpool and a BSc in Physics from the University of Ioannina, Greece.

His main research interest is in the field of Biotechnology, Nano science, targeted eradication of cancer tumour and clinical diagnostics.

After earning his medical degree, Prashanth pursued Medical Oncology training at Calvary Mater Newcastle Hospital, he furthered his education and completed training with a Fellowship in Medical Oncology at The Austin Hospital in Melbourne. Prashanth has extensive research experience and his other qualifications apart from FRACP & PhD (University of Melbourne) include Masters of Science (Biotechnology) from University of Western Sydney and Master of Public Health (Epidemiology and Statistics) from the University of Newcastle. Prashanth has presented at major national and international meetings, and authored publications in prominent cancer related peer reviewed journals. He has a special interest in transitional research and immunotherapy, and is a lead investigator in a number of clinical trials, and also is involved in development and conduct of clinical trials. His research goals are to develop innovative models to establish EMT mechanism as an important biomarker for cancer progression, resistance to therapy and as a biomarker of responsiveness to immune therapy, with the aim of developing/designing EMT-based therapies in cancer.

Translational Research, Immunotherapy

Medical oncology experience 5 years from Aldoaa hospital, Mataria teaching hospital, Nasr institute of health and Consultant clinic.Internal medicine and emergency resident in el-salaam specialist hospital (government specialist centers )2010-2012.Fellowship of radiotherapy.

Radiation and clinical oncology

Medical oncology experience 5 years from Aldoaa hospital, Mataria teaching hospital, Nasr institute of health and Consultant clinic.Internal medicine and emergency resident in el-salaam specialist hospital (government specialist centers )2010-2012.Fellowship of radiotherapy.

Radiation and clinical oncology

Dr. David B Pearlstone is a Surgical Oncology Specialist in Easton, Connecticut. He graduated with honors from New York University School Of Medicine in 1989. Having more than 29 years of diverse experiences, especially in SURGICAL ONCOLOGY, He is an Executive director for HealthHavenHub and he was an medical director for VITAS Healthcare Dr. David B Pearlstone affiliates with Middlesex Hospital, and cooperates with other doctors and specialists without joining any medical groups.

Surgical oncologist

Giannoula Lakka Klement, MD, F.R.C.P.(C) received her MD in 1992 from McMaster University in Hamilton, Ontario. She finished her Fellowship in Pediatric Hematology/Oncology at the Hospital for Sick Children, University of Toronto in 1997. she decided to focus her research on developing novel antiangiogenic treatments. She received the prestigious National Cancer Institute of Canada Terry Fox Postgraduate Research Fellowship in 1997 to do this work, and joined the laboratory of a prominent scientist, Dr. Robert Kerbel, at the Sunnybrook & Women's College Health Sciences Center, University of Toronto. Her post–doctoral work led to the first publication on metronomic chemotherapy, and caused a paradigm shift in our thinking about anti-cancer therapy. Metronomic chemotherapy continues to be explored in numerous clinical trials, and forms the basis of introduction of most new antiangiogenic agents. In 2003 Dr. Klement moved to Boston to join the research group of the late Dr. Judah Folkman, to continue research in tumor angiogenesis. She developed a Clinical Experimental Therapeutics Program at the Vascular Anomalies Center at Dana-Farber Cancer Institute and Children's Hospital Boston. Realizing that the successful clinical introduction of angiogenesis–based therapeutic strategies will require reliable biomarkers for the detection of early tumor growth and/or therapeutic response, Dr. Klement made detection of circulating biomarkers the focus of her basic science laboratory. She discovered that the majority of angiogenesis regulators, both stimulators and inhibitors of angiogenesis are sequestered in platelets and can be detected in platelets very early in tumor growth. From May 2009 to August 2013 she was an investigator at the Center of Cancer Systems Biology at St. Elizabeth Medical Center. In 2012 she received a generous donation from the Newman-Lakka Cancer Foundation and became the Director of Newman-Lakka Institute for Personalized Cancer Care, which specializes in the treatment of children and adults with difficult to treat cancers using combinations of metronomic and targeted therapies.

Tumor angiogenesis

Alexander Seifalian, Professor of Nanotechnology and Regenerative Medicine worked at the Royal Free Hospital and University College London for over 26 years, during this time he spent a period of time at Harvard Medical School looking at caused of cardiovascular diseases and a year at Johns Hopkins Medical School looking at treatment of liver. He published more than 647 peer-reviewed research papers, and registered 14 UK and International patents. He is currently CEO of NanoRegMed Ltd, working on the commercialisation of his research. During his career Prof Seifalian has led and managed many large projects with successful outcomes in terms of commercialisation and translation to patients. In 2007 he was awarded the top prize in the field for the development of nanomaterials and technologies for cardiovascular implants by Medical Future Innovation, and in 2009 he received a Business Innovation Award from UK Trade & Investment (UKTI). He was the European Life Science Awards’ Winner of Most Innovative New Product 2012 for the “synthetic trachea”. Prof Seifalian won the Nanosmat Prize in 2013 and in 2016 he received the Distinguish Research Award in recognition of his outstanding work in regenerative medicine from Heals Healthy Life Extension Society. His achievements include development of the world first synthetic trachea, lacrimal drainage conduit, and vascular bypass graft using nanocomposite materials, bioactive molecules and stem cell technology. He has over 15,000 media report from his achievement, include BBC, ITV, WSJ, CNN, and many more. Currently he is working on development and commercialisation of human organs using graphene based nanocomposite materials and stem cells technology.

Nanotechnology and Regenerative Medicine

Dr. K. Govind Babu, M.D., DM is a Professor of Medical Oncology at Kidwai Memorial Institute of Oncology, India. Dr. Babu is also a Senior Medical Oncologist at Kidwai Memorial Cancer Hospital. He has been working as medical oncologist for more than 25 years. He has gained a considerable experience in the field of Medical Oncology practising as consultant at the HCG Hospitals in Bangalore and the Kidwai Memorial Institute of Oncology, where he currently serves as Professor of Medical Oncology. Dr. K Govind Babu earned his MD in General Medicine from the Bangalore Medical College and Research Institute, and DM in Oncology from the Kidwai Memorial Institute of Oncology. Dr Babu's key areas of expertise are solid tumors and hemato-oncology and he is keenly involved in targeted therapies and precision medicine. He has authored and co-authored more than 120 publications in national and international journals and text books and has delivered more than 160 presentations at local and worldwide events. He has been awarded several recognitions. He has received training at the Dana Farber and MD Anderson centre in the USA. He is a recipient of many national and international awards and has been a part of many national and international researches, including clinical trials in oncology. Dr. Babu is currently the Vice President of the Indian Society of Medical and Paediatric Oncology (ISMPO).

Targeted therapies,Precision Medicine

Ahmed Abdelgawad Abdelaty is a Surgical Oncologist working in Ismailia Teaching Oncology Hospital and General Surgery Resident Physician at El-Matarya Teaching Hospital (MTH) He also Worked at el hussein hospital Former general surgery resident at El Nasr Hospital Studied at faculty of medicine alazhar university

surgical oncology

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research thirty years ago. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor with Romano Demicheli of a Springer-Nature book published July 2017 (Perioperative Inflammation as Triggering Origin of Metastasis Development). After diagnosis of stage IIIc colon cancer in 1994, he was the first person to use what is now called metronomic chemotherapy He is is a founder and was on the on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer Alliance.

Cancer research, Charged particle optics and Early detection of cancer and delayed detection of cancer